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Plasma amyloid b (Ab) levels have been associated with an increased risk of Alzheimer’s disease (AD). As
depression is common before the onset of AD, a few clinical studies tested the cross-sectional association
of Ab levels with depression in elderly and showed incongruous ﬁndings. Hence, we tested the longi-
tudinal association between Ab levels and depressive symptoms in community-dwelling elderly. The
study is embedded in a population-based cohort of 980 participants aged 60 years or older from the
Rotterdam Study with Ab levels. Participants were evaluated for depressive symptoms with the Centre
for Epidemiological Studies-Depression scale at baseline and repeatedly over the mean follow-up of 11
years. We ﬁrst performed cross-sectional analyses. Then, we tested the longitudinal association between
Ab levels and depressive symptoms after excluding participants with dementia during follow-up. In
cross-sectional analyses, persons with high Ab1-40 levels had more clinically relevant depressive symp-
toms. However, this association was accounted for by persons with clinically relevant depressive
symptoms who developed dementia within the next 11 years. In longitudinal analyses, persons with low
levels of Ab1-40 and Ab1-42 without dementia had a higher risk of clinically relevant depressive symptoms
during the follow-up. These ﬁndings suggest that the cross-sectional association between high plasma
Ab levels and clinically relevant depressive symptoms in the elderly is due to prodromal dementia. In
contrast, the longitudinal association between low plasma Ab levels and depressive symptoms could not
be explained by dementia during follow-up suggesting that Ab peptides may play a distinct role on
depression etiology.
 2013 Elsevier Ltd. Open access under the Elsevier OA license.1. Introduction
Two soluble forms of amyloid b peptides, amyloid b1-40 (Ab1-40)
and amyloid b1-42 (Ab1-42), have been associated with an increased
risk of Alzheimer’s disease (AD) (Schupf et al., 2008; van Oijen et al.,
2006). On the basis of the observation that depression is common
before the onset of AD, several studies have tested the association
of Ab levels with depression in older adults. The ﬁndings of these
cross-sectional studies were inconsistent. While high Ab1-42 levels
in people with depression were found in some studies, an associ-
ation between low Ab1-42 levels and depression was observed iniology, Erasmus University
he Netherlands. Tel.: þ31 10
eier).
sevier OA license.others (Moon et al., 2011; Pomara et al., 2006; Qiu et al., 2007; Sun
et al., 2011, 2009, 2007, 2008). Moreover, to what extent prodromal
dementia contributes to the cross-sectional associations is
unknown. A longitudinal study that excluded all participants with
dementia at baseline or during 5 years of follow-up showed that
higher baseline Ab1-42 levels were associated with incident
depression (Blasko et al., 2010). However, as Ab levels start to
change 5e10 years before the onset of AD (Buchhave et al., 2012),
a longer follow-up is needed to clarify whether this association is
independent of the prodromal effects of AD. In addition, it is
important to explore Ab1-40, as it has not been tested longitudinally.
We therefore investigated the cross-sectional association between
Ab peptides and clinically relevant depressive symptoms with and
without exclusion of persons who developed dementia during the
follow-up. Next, we conducted longitudinal analyses excluding
those who develop dementia during the follow-up.
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2.1. Study sample
This study is embedded in the Rotterdam Study, an ongoing
prospective population-based cohort of older adults (Hofman et al.,
2011), which has been approved by the institutional review board
of Erasmus University Medical Centre and by the review board of
the Netherlands Ministry of Health, Welfare and Sports. All
participants provided written informed consent after receiving
a complete description of the Rotterdam Study.
Baselinemeasurements for the current study were performed at
the examination round between 1997 and 1999. The ﬁrst and the
second follow-up examinations were performed between 2002e
2004 and 2009e2011, respectively. Mean time interval between
baseline and the ﬁrst interview was 4 years (Standard deviation
[SD] ¼ 0.5) and between baseline and the second interview was 11
years (SD ¼ 0.6).
At baseline (1997e1999), 4797 participants were involved in the
study. From this source population, we formed a random sample of
1023 people for Ab1-40 or Ab1-42 measurements. Twenty-two
participants who did not have a valid Centre for Epidemiological
Studies-Depression scale (CES-D) score and 9 participants with
dementia at baseline were excluded from the current study, leaving
992 participants with at least one measurement of Ab. Also, we
excluded participants with Ab1-40 (n ¼ 12) or Ab1-42 (n ¼ 4)
concentrations that were out of the mean range of 3 standard
deviation (SD). The ﬁnal population for cross-sectional analyses
consisted of 980 participants for whom Ab1-40 levels were available
and 970 for whom Ab1-42 levels were available. People who
excluded from the baseline random sample (n ¼ 43) were older
than the participants (p < .001). There was no signiﬁcant gender
difference between participants and non-participants (p ¼ .881).
For the longitudinal analyses, we further excluded 67 partici-
pants with clinically relevant depressive symptoms (CES-D
score 16) at baseline and 107 participants with incident dementia
by the end of the second follow-up (2011). Of the remaining 806
participants, 86 died (10.7%) between baseline and the follow-up
examinations, 58 refused to participate (7.2%) to any follow-up,
and 5 (0.6%) did not have a valid CES-D measurement in any
follow-up. This provided an overall sample of 657 participants with
a valid depression evaluation and at least one Ab measure (partic-
ipants with Ab1-40, n ¼ 657; participants with Ab1-42, n ¼ 650) for
the longitudinal analyses of repeated CES-D measure. A ﬂow
diagram of the study population at baseline and at follow-up visits
was presented in Fig. 1.
2.2. Assessment of Ab levels
Fasting morning blood samples were collected in sodium citrate
containing vacutainers and put on ice immediately after collection.
These samples were centrifuged within 60 min, and aliquots of the
plasma were stored at 80 C. A double-antibody sandwich
enzyme-linked immunosorbent assay (ELISA) method was used to
determine Ab plasma concentrations (van Oijen et al., 2006). The
mean coefﬁcients of within- and between-assays variation were
4.4% and 10.1% for Ab1-40 and 4.9% and 14.8% for Ab1-42. The
detection limits were 10e1000 pg/ml for Ab1-40 and 5e100 pg/ml
for Ab1-42.
2.3. Assessment of depression
We used the CES-D, a self-report scale, for measuring depressive
symptoms at baseline and at follow-up visits (Radloff, 1977). The
CES-D interviews were part of the home interviews, which wereperformed by research assistants whomonitored the completion of
the questions. The CES-D scores were analyzed continuously
(depressive symptom scores) and a cut-off of 16 was used to detect
participants with clinically relevant depressive symptoms. This
score has a very high sensitivity formajor depression in older adults
in the Netherlands (Blazer et al., 1991). Incident clinically relevant
depressive symptoms were deﬁned in participants free of clinically
relevant depressive symptoms at baseline as the CES-D score of 16
or over at one of the follow-up assessments.
For additional analyses, we studied past clinically relevant
depressive symptoms. In the previous examination wave of the
Rotterdam Study (1993e1995), history of clinically relevant
depressive symptomswas evaluatedwith the CES-D or the Hospital
Anxiety-Depression Scale (HADS). We used a cut-off score of 16 for
the CES-D and a cut-off score of 9 for the HADS to detect partici-
pants with clinically relevant depressive symptoms in the past
(Luijendijk et al., 2008).
2.4. Assessment of dementia
Dementia was assessed with multiple sources including diag-
nostic evaluation at follow-up visits and continuous monitoring to
capture more events. Participants were screened for dementia at
baseline and follow-up visits using a 3-step protocol (Ott, Breteler,
van Harskamp, Stijnen, & Hofman, 1998). First, all participants were
screened for the cognitive functions using the Mini Mental State
Examination (MMSE) and Geriatric Mental State Schedule (GMS)
organic level. Then, participants with an MMSE score <26 or a GMS
organic level>0 underwent the Cambridge Examination for Mental
Disorders of the Elderly. Finally, participants whowere suspected to
have dementia were examined by an experienced neuropsycholo-
gist, if necessary. Additionally, participants were continuously
monitored for incident dementia by a computerized system that
synchronized the study databasewith the digitizedmedical records
of general practitioners and the regional Institute for Outpatient
Mental Health Care (Ott et al., 1998; Schrijvers et al., 2012). A
consensus panel of a neurologist, neuropsychologist, and research
physician decided on the ﬁnal diagnose on the basis of the DSM-III-
R criteria for dementia (Williams and Association, 1987) and the
NINCDS-ADRDA for Alzheimer’s disease (McKhann et al., 1984).
Follow-up for incident dementia was complete until January 1,
2011. Participants who were free of dementia at baseline but were
diagnosed with dementia during the maximum follow-up of 13
years were considered as participants with prodromal dementia at
baseline.
2.5. Assessment of covariates
Age, sex, level of education, cognitive functions, creatinine
levels, antidepressant use and cardiovascular risk factors were
considered as possible confounders. Education was grouped into
eight categories in an ordinary scale from primary education (1) to
university level (8). The MMSE was used to evaluate cognitive state
(Folstein et al., 1975) Plasma creatinine level, which is considered as
a determinant of amyloid beta levels (Metti et al., 2012), were
measured with an enzymatic in-vitro assay (Roche, Germany).
Antidepressant use was determined from the cabinet check at
home interviews. Body mass index, smoking status, prevalent
stroke, diabetes mellitus and hypertension were considered as
vascular risk factors. Height (meters) and weight (kilograms) were
measured and body mass index was calculated as weight in kilo-
grams divided by height in meters squared. Smoking status was
categorized as never, former, and current smoker, on the basis of
the baseline interview. Information about prevalent stroke at
baseline was obtained through automated linkage of the study
Fig. 1. Study sample.
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the municipality. Diabetes mellitus was deﬁned as having fasting
blood glucose concentrations 11.1 mmol/L or the use of antidia-
betic medication. Hypertension was deﬁned as a systolic blood
pressure140mmHg, a diastolic blood pressure90mmHg, or the
use of antihypertensive medication.
2.6. Statistical analyses
Ab levels were analyzed continuously. To approach normality,
we log transformed the CES-D scores for the continuous analyses.
We also tested the CES-D scores categorically using the established
cut-off of 16 for clinically relevant depressive symptoms. Ab levels
had normal distribution when we excluded outliers.To estimate the cross-sectional associations between Ab levels
and the odds of clinically relevant depressive symptoms,we ran two
analyses. First, we included all participants with clinically relevant
depressive symptoms as cases at baseline. Second, we deﬁned two
groups of cases with clinically relevant depressive symptoms at
baseline: 1) persons with clinically relevant depressive symptoms
and no dementia during follow-up (n ¼ 54), 2) persons with clini-
cally relevant depressive symptoms and dementia during follow-up
(n ¼ 13). For the second analysis, we used multinomial logistic
regression analysis to compare the two case groups with the refer-
ence group, which consisted of persons free of clinically relevant
depressive symptoms and dementia during follow-up (N ¼ 806).
We tested the longitudinal associations in those who remained
free of dementia during the follow-up. The longitudinal association
Table 1
Baseline characteristics of the study population.
Baseline information Study sample N ¼ 980
Age, mean years (SD) 71.6 (6.8)
Female, n (%) 581 (59.3)
Education (range: 1e8), mean (SD) 3.7 (1.9)
Smoking status
Current smoker, n (%) 160 (16.3)
Former smoker, n (%) 472 (48.2)
Never smoked, n (%) 348 (35.5)
Stroke, n (%) 32 (3.3)
Hypertension, n (%)a 447 (45.6)
Diabetes Mellitus, n (%) 124 (12.7)
Body mass index (kg/m2), mean (SD) 26.9 (3.7)
Mini Mental State Examination score, mean (SD) 27.8 (1.8)
Clinically relevant depressive symptomsb, n (%) 67 (6.8)
History of clinically relevant depressive
symptoms, n (%)
60 (6.1)
Antidepressant use at baseline, n (%) 39 (4)
Creatinine level (mmol/l), mean (SD) 79.4 (17.8)
Amyloid b1-40 (pg/ml), mean (SD) 205.6 (62.5)
Amyloid b1-42 (pg/ml), mean (SD) 18.6 (8.4)
Abbreviations: SD ¼ Standard Deviation.
a In total, 945 participants had hypertension data.
b People with a CES-D score 16 are considered as people with clinically relevant
depressive symptoms.
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assessed with the Generalized Estimating Equations (GEE), to
combine the scores from follow-up visits. This statistical method
increases the power and reduces the type I error caused bymultiple
testing, but also takes account of the correlation between the
repeated depression measures. To study the short- and long-term
follow-up associations of Ab levels with depressive symptom
scores at ﬁrst and second follow-up visits, we additionally per-
formed linear regression analyses. Finally, we used the GEE method
with a binary logistic function to predict incident clinically relevant
depressive symptoms during the mean follow-up of 11 years.
Additionally, we used logistic regression analyses to investigate the
associations at individual follow-up visits.
All analyses were adjusted for age and gender. Additional
covariates including education, MMSE score, plasma creatinine
levels, and antidepressant use were entered into the model. To
investigate to what extent any association of Ab levels with
depressive symptoms is explained by an effect on vascular risk
factors, we additionally controlled the GEE analyses for vascular
risk factors including smoking status, body mass index, prevalent
stroke, hypertension and diabetes mellitus.Table 2
Cross-sectional associations between Ab levels and clinically relevant depressive sympto
All clinically relevant depressive
symptomsb (n ¼ 67)
Clinically rel
without prod
OR 95% CI p OR
Ab1-40 (per SD)
Model 1 1.20 0.95e1.52 0.12 1.07
Model 2 1.34 1.04e1.71 0.02 1.17
Ab1-42 (per SD)
Model 1 1.09 0.87e1.37 0.45 0.98
Model 2 1.12 0.89e1.41 0.32 1.00
Abbreviations: Ab, Amyloid beta; OR, Odds ratio; CI, Conﬁdence interval; SD, Standard d
Model 1 is adjusted for age and gender and model 2 is adjusted for age, gender, educati
a Persons with a CES-D score 16 or greater are considered as persons with clinically r
b Logistic regression analyses were used to test the cross-sectional association between
population.
c We tested the cross-sectional associations of Ab levels with clinically relevant depress
using multinomial logistic regression analyses. We used persons free of clinically relevan
category.We performed a series of sensitivity analyses. First, to test the
possible reverse causality,weexcludedparticipantswith ahistory of
clinically relevant depression and performed additional GEE anal-
yses. Second, to test thepossible effectof includingextremevalues of
Ab (those above 3 SD) on the associations, we performed sensitivity
analyses assigning the outlier values to the value equivalent to 3 SD
and repeated the GEE analyses. Finally, we performed a sensitivity
analysis considering antidepressant users at follow-up visits as
personswith clinically relevant depressive symptoms. Thismakes it
possible any misclassiﬁcation of persons with clinically relevant
depressive symptoms that were successfully treated.
SPSS version 17 was used for statistical analyses. A two-sided
p < .05 was considered to indicate statistical signiﬁcance.
3. Results
The baseline characteristics of the study sample are presented in
Table 1. The mean age was 71.6 years (SD ¼ 6.8), and 581 (59.3%) of
the participants were female. At baseline, 67 (6.8%) participants had
clinically relevant depressive symptoms.
The fully adjusted cross-sectional analyses showed that the
likelihood of having clinically relevant depressive symptoms was
34% higher per standard deviation increase in Ab1-40 levels
(Table 2). However, when we categorized participants on the basis
of whether they developed dementia during follow-up in a further
analysis, we found that this association was accounted for by
persons with clinically relevant depressive symptoms that
preceded incident dementia (prodromal dementia). Per standard
deviation increase in Ab1-40 levels were related to an approximately
two times higher likelihood of having clinically relevant depressive
symptoms in participants who developed dementia during follow-
up compared to the non-depressed reference group. Ab1-42 levels
were not related with clinically relevant depressive symptoms in
the cross-sectional analyses (Table 2).
The longitudinal analyses of repeated CES-D measurements
showed that high Ab1-40 and Ab1-42 levels at baseline were asso-
ciated with a decreased risk of having high depressive symptom
scores. As Table 3 shows, lower Ab1-40 and Ab1-42 levels were
associated with higher depressive symptom scores at the ﬁrst
follow-up in those free of dementia during follow-up visits. At the
second follow-up visit, there were also inverse associations
between Ab levels and depressive symptom scores, but neither of
these associations was statistically signiﬁcant. Combining two CES-
D measurements in different time points increased the precision of
estimate as can be seen by the narrower CIs in GEE analyses when
compared to the analyses of the individual follow-up visits.ms by prodromal dementia status (n ¼ 980).a
evant depressive symptoms
romal dementiac(n ¼ 54)
Clinically relevant depressive symptoms
with prodromal dementiac (n ¼ 13)
95% CI p OR 95% CI p
0.82e1.40 0.61 1.65 1.04e2.62 0.03
0.88e1.55 0.29 2.22 1.33e3.73 0.002
0.74e1.29 0.87 1.24 0.86e1.79 0.25
0.76e1.32 0.98 1.34 0.92e1.95 0.12
eviation.
on, Mini Mental State Examination score, creatinine levels, and antidepressant use.
elevant depressive symptoms.
Ab levels and clinically relevant depressive symptoms at baseline in the total study
ive symptoms ﬁrst in persons with and then in persons without prodromal dementia
t depressive symptoms and free of prodromal dementia at baseline as the reference
Table 3
Longitudinal associations between Ab levels and depressive symptoms in participants free of dementia during follow-up visits.
Depressive symptom scores (continuous)
Repeated scoresa First follow-upb Second follow-upb
N Beta 95% CI p N Beta 95% CI p N Beta 95% CI p
Ab1-40 (per SD)
Model 1 657 0.09 0.16; 0.02 0.01 638 0.09 0.17; 0.02 0.02 451 0.08 0.17; 0.01 0.07
Model 2 657 0.10 0.17; 0.03 0.01 638 0.11 0.19; 0.03 0.01 451 0.08 0.18; 0.01 0.08
Ab1-42 (per SD)
Model 1 650 0.10 0.16; 0.03 0.003 632 0.12 0.20; 0.04 0.004 443 0.07 0.16; 0.03 0.15
Model 2 650 0.11 0.17; 0.04 0.001 632 0.12 0.20; 0.05 0.002 443 0.08 0.17; 0.02 0.12
Clinically relevant depressive symptoms (categorical)
Repeated symptomsa First follow-upc Second follow-upc
N OR 95% CI p N OR 95% CI p N OR 95% CI p
Ab1-40 (per SD)
Model 1 657 0.84 0.68; 1.04 0.11 638 0.99 0.78; 1.27 0.96 451 0.61 0.42; 0.89 0.04
Model 2 657 0.83 0.66; 1.04 0.11 638 0.95 0.74; 1.23 0.71 451 0.66 0.45; 0.98 0.04
Ab1-42 (per SD)
Model 1 650 0.69 0.54; 0.88 0.002 632 0.77 0.58; 1.03 0.09 443 0.57 0.39; 0.84 0.01
Model 2 650 0.67 0.52; 0.86 0.002 632 0.73 0.54; 0.99 0.04 443 0.60 0.41; 0.89 0.01
Abbreviations: SD, Standard deviation; CI, Conﬁdence interval; OR, Odds ratio.
Model 1 is adjusted for age and gender and model 2 is adjusted for age, gender, education, Mini Mental State Examination score, creatinine levels, and antidepressant use.
a The generalized estimating equations for repeated CES-D scores or incident clinically relevant depressive symptoms (CES-D  16) at two follow-up visits were presented.
b Linear regression analyses were presented at follow-up visits separately. The CES-D scores were natural log transformed due to the positively skewed distribution.
c Logistic regression analyses were presented at follow-up visits separately.
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consistent results. Lower Ab1-42 levels were associated with
a higher risk of clinically relevant depressive symptoms (Table 3) in
the combined analyses. At the ﬁrst follow-up, there was a border-
line signiﬁcant association between Ab1-42 levels and incident
clinically relevant depressive symptoms, whereas that association
was clearly signiﬁcant at the second follow-up. There was an
inverse relation also between Ab1-40 levels and clinically relevant
depressive symptoms at the second follow-up, but this association
was not observed when we used the GEE method.
Additional adjustment for vascular risk factors or excluding
participants with a history of clinically relevant depressive symp-
toms did not improve the model in the additional GEE analyses
(data not shown). Sensitivity analyses in which we assigned the
extreme outlier values equivalent to 3 SD did not change the results
of the GEE analyses (data not shown). When we considered anti-
depressant users as persons with clinically relevant depressive
symptoms (cases), our results did not change marginally (data not
shown).
4. Discussion
This population-based cohort study explored the cross-sectional
and longitudinal associations of Ab peptides with depressive
symptoms in elderly people. Participants with high levels of Ab140
were more likely to have prevalent clinically relevant depressive
symptoms but only if they developed dementia during follow-up.
Longitudinal analyses showed that lower plasma concentrations
of Ab1-40 and Ab1-42 were associated with a higher risk of clinically
relevant depressive symptoms and lower levels of Ab1-42 predicted
incident clinically relevant depressive symptoms during the mean
follow-up of 11 years.
The relation of plasma Ab levels with depression has been
tested mostly in cross-sectional studies. A series of studies by one
group found lower levels of plasma Ab1-42 in patients with
depressive symptoms, whereas plasma Ab1-40 levels were not
related to depressive symptoms (Qiu et al., 2007; Sun et al., 2011,
2009, 2007, 2008). However, these results have not been
conﬁrmed by other studies (Kita et al., 2009; Moon et al., 2011;Pomara et al., 2006) and it is not clear whether these associations
are due to changes in Ab levels before the onset of overt dementia.
The present cross-sectional analyses showed a positive association
between Ab1-40 levels and clinically relevant depressive symp-
toms. However, this association was accounted for by participants
with dementia during follow-up (i.e. those are at the latent or
prodromal phase of dementia at baseline) (Welsh-Bohmer, 2008).
This ﬁnding is also in line with a previous report from the Rot-
terdam Study, which showed that high Ab1-40 but not Ab1-42 levels
predict dementia many years prior to onset of clinical disease (van
Oijen et al., 2006).
Plasma Ab levels change 5e10 years before the onset of AD
(Buchhave et al., 2012; Graff-Radford et al., 2007). Therefore, it is
important to consider the new-onset dementia occurring after
baseline when exploring the independent association of Ab levels
with depression. Only one longitudinal study with 5 years of
follow-up by Blasko et al. excluded new-onset dementia (Blasko
et al., 2010). Blasko et al. found that high plasma Ab1-42 levels
were associated with the ﬁrst episode of late onset depression, in
contrast to our prospective cohort study with a more than 10 years
of follow-up for depressive symptoms and dementia.
Several mechanisms may explain the inverse relation between
plasma Ab levels and depressive symptoms that we found in our
longitudinal analyses. As cerebral and peripheral levels of Ab are
probably in dynamic equilibrium (Wang et al., 2006), any deposi-
tion of Ab peptides in the brain may reduce the plasma levels of Ab.
These brain depositions occur in the neurons and in cerebral vessels
whichmay play a role in the etiology of depression (Iadecola, 2003;
Roy and Rauk, 2005). Neurotoxic effects are characterized by
a damage to serotoninergic, noradrenergic and cholinergic markers
in neurons (Gonzalo-Ruiz et al., 2003) and increased free radical
production (Roy et al., 2005). Furthermore, Ab peptide aggregations
in small cerebral vessels can decrease cerebral blood ﬂow and
glucose utilization. This may cause white-matter lesions and
lacunar infarcts in the brain and precipitate late life depression
(Alexopoulos et al., 1997; Direk et al., 2012; Gurol et al., 2006;
Iadecola, 2003; van Dijk et al., 2004). However, our analyses
showed that adjustment for the common vascular risk factors did
not change the results substantially.
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Reversed causality might be responsible for the observed associa-
tions. Reversed causality occurs if the outcome is causally related to
the exposure. Depressive symptoms before baseline could have
altered Ab levels by the increased platelet activation, which can
stimulate Ab release to the circulation (Canan et al., 2011;
Musselman et al., 1996; Skovronsky et al., 2001). However,
excluding the participants with a history of clinically relevant
depressive symptoms did not change the results in our study.
Residual confounding due to unmeasured or unknown
confounders e.g. diet, physical activity, non-clinical cerebrovascular
changes, etc., which are associated with both Ab levels and
depression, cannot be ruled out and may partially explain our
observations (Rothman et al., 2008).
There are several strengths of the current study. First, the large
study sample and existence of numerous data collection enabled us
to evaluate a large number of covariates. Second, the population-
based setting increased the generalizability of the ﬁndings. Third,
the prospective design allowed us to assess the temporal associa-
tion between Ab peptides and depressive symptoms. Finally, eval-
uation of the mediating effect of dementia was rendered possible
by complete screening for new-onset dementia during follow-up.
Some limitations in our study should be mentioned. Depression
was evaluated with the CES-D, which is commonly used in
population-based studies to evaluate clinically relevant depressive
symptoms. Therefore, it remains unansweredwhether these results
can be generalized to clinical depressive disorders. Second, loss to
follow-up was not very substantial, but may yet be a source of
downward bias because participants with clinically relevant
depressive symptoms are underrepresented in the study pop-
ulation. However, we had enough power to observe an association
between Ab levels and depressive symptoms. Finally, long time
interval between baseline and follow-up interviews may affect our
results as those persons with chronic or recurrent depressive
symptoms are more likely to be identiﬁed as a case. However, when
we consider antidepressant users as persons with clinically rele-
vant depressive symptoms, our results did not change largely.
In conclusion, decreased Ab levels were associated with clini-
cally relevant depressive symptoms in participants free of dementia
during follow-up. Our study provides evidence that Ab peptides
may play a role in aetiology of depression independent of dementia.
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